Katalog der Deutschen Nationalbibliothek

Go to:

Catalogue (Beta)

Knowledge Web

Person
Person

Person

Jens Siveke (1973-)

Name

Jens Siveke

Time

1973- (Date of birth and death)

Place

Deutschland

Gender

männlich

Academic degree

Prof. Dr. med.

Variant

Jens Thomas Siveke
Jens T. Siveke

Related

Universitätsklinikum Essen
Deutsches Krebsforschungszentrum

Further information

Am Deutschen Konsortium für Translationale Krebsforschung (DKTK)", Standort Universitätsklinikum Essen tätig

Record type

Person

GND-Identifier

123603498

Record ID

123603498

Involved in

show all

P-move: a randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapy

Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatment

Characterization and targeting of ribosome biogenesis in cellular and tissue subtypes of pancreatic ductal adenocarcinoma

Exploiting genetic vulnerabilities for BAP1 loss by synthetic lethality

Molekulare Charakterisierung von Cholangiokarzinomen mit Fokus auf DNA Schadensreparaturgene in einem onkologischen Spitzenzentrum

Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols

A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)

Evaluation of a liquid biopsy approach in pancreatic ductal adenocarcinoma

MCL1 as putative target in pancreatoblastoma

Das Pankreaskarzinom : Klinische Projekte der onkologischen Studiengruppen in Deutschland (ACO, AIO und ARO)

Epigenetic and phenotypic plasticity as mediators of resistance to oncogenic pathway targeting

Exploring Tumor-Associated Macrophage Heterogeneity and Their Responses to MEK Inhibition in Pancreatic Ductal Adenocarcinoma

TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer

Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma

[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma

Localized angiosarcoma, not one disease: a retrospective single-center study on prognosis depending on the primary site and etiology

Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma

Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus : a randomized, placebo-controlled phase II AIO trial with serum biomarker program

T-Helferzellen vom Th1-, Th2-Typ : chemokin-induzierte Chemotaxis und Chemokinrezeptor-Expression

T-Helferzellen vom Th1-Th2-Typ : chemokin-induzierte Chemotaxis und Chemokinrezeptor-Expression
Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

DNB portal